Roche's Fuzeon will not be discussed in health insurance meeting next month

Published: 2008-03-03 07:00:00

Updated: 2008-03-03 07:00:00

Roche Korea's anti-AIDS agent Fuzeon (enfuvirtide) will be exclusive from the government's health insurance meeting to be held next month, according to the Ministry of Health and Welfare.

The ministry officials said that Fuzeon may be replaced by other medicines in combating drug resistance in...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK